Para-Methoxyphenylpiperazine
| Clinical data | |
|---|---|
| Other names | pMeOPP; pMPP; p-MeOPP; p-MPP; 4-MeOPP; 4-MPP; MeOPP; MPP; Paraperazine | 
| Routes of administration | Oral | 
| ATC code | 
 | 
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | The human liver P450 CYP2D6 converts para-methoxyphenylpiperazine by demethylation to para-hydroxyphenylpiperazine. | 
| Excretion | Renal | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.048.918 | 
| Chemical and physical data | |
| Formula | C11H16N2O | 
| Molar mass | 192.262 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (what is this?) (verify) | |
para-Methoxyphenylpiperazine (pMeOPP), also known as 4-methoxyphenylpiperazine (4-MeOPP), is a substituted piperazine derivative with stimulant effects which has been sold as an ingredient in "Party pills", initially in New Zealand and subsequently in other countries around the world.